Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelionwhich acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.
What is Setipiprant?
Setipiprant is an oral drug that’s currently being tested for use as a hair loss treatment. It was initially developed as a treatment for allergic rhinitis, but recent hair loss-related discoveries have made it a better candidate for hair loss reversal.
How Does It Work?
In short, setipiprant is an antagonist of the prostaglandin D2 receptor 2 (DP2). This receptor is responsible for bonding with and responding to certain prostaglandins, particularly PGD2. This prostaglandin has been linked to various pathological responses, including those linked to allergies, asthma, and inflammation.
As setipiprant is believed to interfere with the receptors known to contribute to allergies/allergic responses, the drug was first tested on allergies and asthma.
In clinical trials, the drug performed quite well in the treatment of allergen-induced airway responses in asthmatic patients. It was also well tolerated by participants. However, its results were similar to those of drugs already on the market, so further trials were discontinued.
For Hair Loss
In 2012, researchers discovered a link between the PGD2 receptor and hair loss. More specifically, this receptor is seen at high levels in the scalps of men diagnosed with Androgenetic Alopecia (AGA).
For more detail information, please feel free to contact me.